|
|
||||||||
J Thorac Cardiovasc Surg 2008;135:91-97
© 2008 The American Association for Thoracic Surgery
Surgery for Congenital Heart Disease |
a Division of Cardiology, The Childrens Medical Center at Dallas, Dallas, Tex
b Department of Medicine (Medical Genetics), University of Washington, Seattle, Wash
c Division of General Pediatrics, The Childrens Hospital of Philadelphia, Pa
d Division of Cardiology, The Childrens Hospital of Philadelphia, Pa
e Division of Psychology, The Childrens Hospital of Philadelphia, Pa
f Division of Genetics, The Childrens Hospital of Philadelphia, Pa
g Division of Neurology, The Childrens Hospital of Philadelphia, Pa
h Division of Cardiothoracic Anesthesia, The Childrens Hospital of Philadelphia, Pa
i Division of Cardiothoracic Surgery, The Childrens Hospital of Philadelphia, Pa.
Research presented at the American Heart Association Scientific Sessions 2004, Orlando, Florida, November 7-10, 2004.
Received for publication February 1, 2007; revisions received April 19, 2007; accepted for publication April 26, 2007. * Address for reprints: Ilana Zeltser, MD, Division of Cardiology, The University of Texas at Southwestern Medical Center, Childrens Medical Center at Dallas, 1935 Motor Street, Dallas, TX 75235. (Email: ilana.zeltser{at}childrens.com).
| Abstract |
|---|
|
|
|---|
Methods: We performed a subgroup analysis of children with tetralogy of Fallot undergoing complete repair before 6 months of age who were enrolled in a trial assessing apolipoprotein E genotype as a predictor of neurodevelopmental outcome. Assessment included genetic evaluation, neurologic examination, and the Bayley Scales of Infant Development-II, yielding the Mental Developmental Index and Psychomotor Developmental Index.
Results: Sixty children were tested at 1 year of age. A confirmed or suspected genetic syndrome was identified in 18.3%. The mean Mental Developmental Index was 89 ± 13, and the mean Psychomotor Developmental Index was 81 ± 17. Scores for the Mental Developmental Index (76 ± 13 vs 92 ± 11) and Psychomotor Developmental Index (63 ± 13 vs 85 ± 15) were significantly lower for patients with genetic syndromes. The presence of a genetic syndrome was a predictor of lower Mental Developmental Index and Psychomotor Developmental Index (P = .002 and P = .001). The presence of tetralogy of Fallot with pulmonary atresia and the apolipoprotein E
2 allele were predictive of a lower Mental Developmental Index (P = .001 and P = .035). No other preoperative or operative variables were predictive of worse neurodevelopmental outcome.
Conclusions: At 1 year of age after repair of tetralogy of Fallot, most patients had neurodevelopmental scores within the normal range. Genetic syndromes and the apolipoprotein E
2 allele were important risk factors for neurodevelopmental dysfunction and accounted for some interindividual differences in outcome.
| Introduction |
|---|
|
|
|---|
TOF is a phenotypic feature or an associated clinical finding of many genetic syndromes and chromosomal anomalies associated with impaired ND.11
As many as 16% of patients with TOF have 22q11 microdeletions, Down syndrome, Alagilles syndrome, Cat Eye syndrome, or CHARGE and VATER associations.11-15
Overall, patients with TOF have been noted to have poorer ND outcomes than the healthy population.3,16
DeMaso and associates17
reported that 22% of patients with TOF, most of whom underwent complete surgical repair, scored less than 80 on standardized intelligence quotient testing, approximately 1.5 standard deviations (SDs) less than the expected mean score of 100. Few data are available regarding ND outcomes for patients after surgical repair of TOF in infancy wherein confounding genetic variables are taken into consideration.
In addition, genetic polymorphisms exist that may impair neuroresiliency and increase susceptibility to neurologic injury after infant heart surgery. Apolipoprotein E (APOE) is an important regulator of cholesterol metabolism in the central nervous system and plays a pivotal role in the mobilization and redistribution of cholesterol and phospholipids during neuronal remodeling.18,19
Specifically, APOE e2 allele carriers have been shown to have lower scores on the Psychomotor Development Index (PDI) of the Bayley Scales of Infant Development-II at 1 year of age after neonatal and infant cardiac surgery.20
The purpose of this study was to determine the frequency of abnormal ND outcomes in 1-year-old patients with TOF after surgical repair. In addition, we sought to determine the role of genetic factors, including APOE polymorphisms, as determinants of poor ND outcomes in this patient population.
| Materials and Methods |
|---|
|
|
|---|
Patient Population
Between October of 1998 and April of 2003, infants with TOF (TOF/pulmonary stenosis or TOF/pulmonary atresia) undergoing complete biventricular repair by the age of 6 months were eligible for the study. Infants with TOF/absent pulmonary valve and TOF/pulmonary atresia with multiple aortopulmonary collaterals were excluded. Other exclusion criteria included (1) major recognizable congenital defects, (2) recognizable genetic or phenotypic syndrome other than chromosome 22q11 microdeletions, and (3) language other than English spoken at home.
Operations were performed at a single institution by 4 cardiac surgeons with a team of dedicated cardiac anesthesiologists. Alpha-stat blood gas management was used. DHCA was used at the discretion of the surgeon. Before DHCA, patients underwent cooling with topical hypothermia and CPB to a nasopharyngeal temperature of 18°C. Modified ultrafiltration was performed in all patients.
One-year Neurodevelopmental Examination
The protocol for ND examination has been described.20
In short, children were evaluated at 12 months of age ± 2 weeks, adjusted appropriately for prematurity. Development was assessed by the Bayley Scales of Infant Development-II, which is composed of 2 separate scores. The PDI assesses fine and gross motor skills, and the Mental Developmental Index (MDI) evaluates cognition, language, memory, problem-solving, and social skills. Both the PDI and MDI yield scores that are normalized to a mean of 100 ± 15. Therefore, a score of 70 or less is greater than 2 SDs below the mean.
In addition, the neurologic evaluation included a medical history, growth measurements, and a complete neurologic examination assessing active and passive tone, reflexes, gross motor skills, and visual and auditory responses by a single developmental pediatrician. The results of the neurologic examination were considered "normal" if no abnormalities or only mild abnormalities that did not affect motor skills were found, "suspect" when there was a moderate degree of abnormality, and "abnormal" when significant abnormalities of tone, reflexes, or motor skills were present. Microcephaly was defined as a head circumference less than or equal to the 5th percentile for age.
Patients were also evaluated by a genetic dysmorphologist. Given the difficulty in detecting dysmorphic features and genetic syndromes in the neonatal period, some children with unrecognized genetic abnormalities had been enrolled as infants. Chromosome analysis and testing for microdeletions of chromosome 22q11 were performed as indicated.
Statistical Analysis
Continuous data are expressed as mean ± SD. Independent t tests were used for comparison of continuous variables, and chi-square and Fisher exact tests were used for comparison of discrete variables as appropriate. Regression analysis was used to assess the association between risk factors and PDI and MDI scores. Initial univariate analysis was performed on potential predictors of ND outcome, including gestational age, ethnicity, socioeconomic status, birth weight, birth length, birth head circumference, sex, delivery method (caesarean or vaginal), multiple gestation birth, 1- and 5- minute Apgar scores, preoperative intubation and prostaglandin use, presence of a confirmed or suspected genetic syndrome, APOE genotype, age and weight at the time of surgery, extracorporeal membrane oxygenation/left ventricular assist device, delayed sternal closure, hematocrit (first value obtained on bypass after hemodilution), intraoperative support time (CPB and DHCA), number of operations and episodes of CPB, and use and duration of DHCA. With respect to the APOE genotype analysis, subjects were grouped into the
2 group (
2
2 and
2
3),
3
3 group, and
4 group (
3
4 and
4
4). Two patients with
2
4 were excluded from the analysis because of the opposing effects of
2 and
4 in Alzheimer disease.
Variables that were marginally significant at P less than .10 were then included in stepwise multivariable regression analysis to identify independent predictors, and the most parsimonious model was used. Because the presence of a confirmed or suspected genetic syndrome was such a strong univariate predictor of ND outcome, the cohort was divided on the basis of whether a genetic syndrome was detected. Separate multivariable analyses were performed on each of these groups predictors.
| Results |
|---|
|
|
|---|
The baseline characteristics and intraoperative details are presented in Table 1. Overall, there was no gender predominance in our patient population. Fifty-nine patients (98%) underwent a single surgical procedure. One patient required reoperation before testing at 1 year. DHCA was used in 22 procedures (37%). Five patients (8%) required multiple periods of CPB during the initial repair. There was no statistical difference in baseline characteristics between the study group and those enrolled patients who did not return for ND testing. However, longer CPB, and therefore total support, times had been used for those patients who did not return for a 1-year assessment compared with the study group.
|
Neonatal recognition of dysmorphic features may be difficult; therefore, some patients were enrolled in whom the diagnosis of a genetic syndrome was not made until the 1-year evaluation. Therefore, although patients with recognized genetic syndromes (eg, trisomy 21), except for 22q11 microdeletions, were not enrolled, a confirmed or suspected genetic syndrome was identified at the 1-year evaluation in 18.3% of the patients. Testing for 22q11 microdeletions was performed in 57 of 60 patients (95%) and identified in 6 patients. Overall genetic syndromes were identified in 11 patients, including 22q11 (6), CHARGE association (2), VATER association (1), Holt-Oram (1), and an undiagnosed syndrome (1). The APOE allele frequencies were 5.8%, 76.7%, and 17.5% for
2,
3, and
4, respectively, as expected for a primarily white population. There were no
2
2 carriers in this study population.
For the entire cohort, the mean MDI was 89 ± 13 and the mean PDI was 81 ± 17. When the scores were analyzed in the context of an underlying genetic syndrome (Figure 1), scores for the MDI were significantly lower for those with a genetic syndrome (76 ± 13) versus those without (92 ± 11). Only 4% (2/49) without an underlying genetic syndrome scored below 2 SDs of normal on the MDI, in contrast with 27.2% (3/11) with a genetic syndrome who scored below 2 SDs of the norm. Similarly, scores for the PDI were significantly lower for those with a genetic syndrome (63 ± 13) versus those without (85 ± 15) (Figure 2). Fourteen percent of patients (7/49) without a genetic syndrome scored below 2 SDs of normal on the PDI, compared with 63.6% of patients (7/11) with a genetic syndrome. Of note, there was no difference between MDI and PDI scores among those with a genetic syndrome when specifically comparing those with the 22q11 microdeletion (n = 6) versus those without (n=5).
|
|
2 allele, most 1-year-old children had normal MDI scores (91 ± 2), with only 7.3% (4/55) scoring below 2 SDs of normal. In contrast, APOE
2 allele carriers had lower MDI scores (78 ± 8) compared with those without the
2 allele, of whom 40% (2/5) scored below 2 SDs of normal. PDI scores did not vary across APOE genotypes.
Table 2
shows the univariate regression results for factors predicting MDI and PDI at a P value less than .10, the cutoff used for inclusion in the multivariate analysis. Table 3
shows the final models, based on stepwise regression analysis. The presence of a genetic syndrome was identified as a predictor of lower MDI (P = .02) and PDI (P < .001) scores in the final models. In addition, the presence of an APOE
2 allele (P = .02) and diagnosis of TOF with pulmonary atresia (P < .001) were predictive of lower MDI scores in the multivariate analysis. When only subjects with no genetic syndrome were considered, the APOE
4 allele was also associated with a decreased MDI score. No predictors other than the presence of a genetic syndrome were significantly associated with the PDI score in the final models. Birth weight, gestational age, socioeconomic status, and age at surgery were not predictive of adverse ND outcomes. Intraoperative variables, including use or duration of DHCA, total support time, and surgeon, were not significantly associated with lower ND scores in the final models.
|
|
| Discussion |
|---|
|
|
|---|
Despite the intended exclusion of patients with recognizable genetic or phenotypic syndromes other than chromosome 22q11 microdeletions, 18.3% of our study patients were subsequently found to have a genetic syndrome, underscoring the prevalence of genetic abnormalities in patients with TOF. The most common genetic disorder was 22q11 microdeletion, consistent with reports citing up to a 16% incidence of 22q11 microdeletion in patients with TOF.12
In a psychoeducational profile performed by Moss and associates,21
patients with 22q11 microdeletions had significant weakness in visual-spatial perception, problem-solving, nonverbal reasoning, and impaired novel reasoning and concept formation, despite receiving special education for those areas. These results reflect more recent findings by Gerdes and coworkers22
and Maharasingam and coworkers,23
who independently demonstrated profound delays in speech and language development in patients with 22q11 microdeletions that were independent of underlying cardiac disease or need for cardiac surgery.
In addition, genetic polymorphisms may influence a persons ability to recover from a neurologic insult. Specifically, APOE is the primary lipid transporter in the central nervous system. Its primary function is maintenance of cell membrane integrity in the neuronal cytoskeleton. APOE synthesis is up-regulated in response to neuronal injury and plays a crucial role in neuronal repair.18
There are 3 common isoforms of APOE, which are encoded by 3 alleles:
2,
3, and
4. In adults, the
4 allele has been implicated as a risk factor for outcomes after central nervous system ischemia, traumatic brain injury, and cardiac surgery.24,25
More recently, Gaynor and associates20
found the APOE
2 allele predicts worse ND outcome at 1 year of age after infant repair of congenital heart defects. The current study addresses the subset of patients with TOF from that larger study. In the current study, APOE
2 and
4 allele carriers had significantly lower MDI scores, implicating APOE genotype as a predictor in ND dysfunction after infant cardiac surgery for TOF.
Over the years, attention has been focused on the use of CPB during infancy as a cause of poor ND outcome. In this study, abnormal MDI and PDI scores were not related to intraoperative variables. Specifically, the age at the time of surgery, the use or duration of DHCA, and the total support time were not associated with worse scores. Although the neurologic sequelae of CPB have been extensively studied in adults, their impact on childhood neurodevelopment remains controversial. Prolonged duration of DHCA has been implicated by many as a significant risk factor for worse ND outcome, observing that risk increases when the duration of DHCA exceeds 45 to 50 minutes.7,9,10,26,27
In our study, the mean duration of DHCA was 30.7 minutes and neither the use nor the duration of DHCA was a risk factor for adverse ND outcome. This is similar to the findings published by Kaltman and associates,28
in which the duration of DHCA was not a risk factor for poor neurologic outcome after infant surgical closure of ventricular septal defects. The current study and others support the hypothesis that patient-specific factors are important determinants of ND outcomes after neonatal and infant cardiac surgery and contribute more substantially to the risk of adverse ND outcomes than do intraoperative management strategies.29
| Limitations |
|---|
|
|
|---|
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. W. Gaynor, M. Gerdes, A. S. Nord, J. Bernbaum, E. Zackai, G. Wernovsky, R. R. Clancy, P. J. Heagerty, C. B. Solot, D. McDonald-McGinn, et al. Is cardiac diagnosis a predictor of neurodevelopmental outcome after cardiac surgery in infancy? J. Thorac. Cardiovasc. Surg., December 1, 2010; 140(6): 1230 - 1237. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fuller, A. S. Nord, M. Gerdes, G. Wernovsky, G. P. Jarvik, J. Bernbaum, E. Zackai, and J. W. Gaynor Predictors of impaired neurodevelopmental outcomes at one year of age after infant cardiac surgery, Eur J Cardiothorac Surg, July 1, 2009; 36(1): 40 - 48. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |